Condition: Pancreatic Cancer, Metastatic · PDAC - Pancreatic Ductal Adenocarcinoma · Sponsor: Engeneic Pty Limited
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Chan Soon-Shiong Institute for Medicine | El Segundo, California, United States | Active Not Recruiting |
| Atlantic Health | Summit, New Jersey, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Taylor Cancer Center | Maumee, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07049055